Multicentric, prospective open-label study to assess the efficacy and safety of Tocilizumab in subjects with refractory myositis Multicentric, prospective open-label study to assess the efficacy and safety of Tocilizumabin subjec ...
Multicentric, open-label, prospective study of subcutaneous tocilizumab in adult patients with refractory myositis - ToReMy Multicentric, open-label, prospective study of subcutaneous tocilizumabin adult patients with refrac ...
Myositis (dermatomyositis [DM] or polymyositis [PM]) MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 20.0;Classification code 10028653;Term: Myositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 20.0;Classification code 10036102;Term: Polymyositis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] Myositis (dermatomyositis [DM] or polymyositis [PM]) MedDRA version: 20.0;Level: PT;Classification c ...